Compare CIB & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIB | INCY |
|---|---|---|
| Founded | 1945 | 1991 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 23.7B |
| IPO Year | 2025 | 1994 |
| Metric | CIB | INCY |
|---|---|---|
| Price | $91.94 | $119.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 28 |
| Target Price | $84.72 | ★ $130.92 |
| AVG Volume (30 Days) | 240.1K | ★ 1.9M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.15% | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $5.76 | $17.47 |
| Revenue Next Year | $7.43 | $4.45 |
| P/E Ratio | ★ $10.87 | $245.70 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $59.64 | $89.25 |
| 52 Week High | $105.60 | $132.60 |
| Indicator | CIB | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 52.76 |
| Support Level | $88.82 | $119.12 |
| Resistance Level | $94.21 | $119.29 |
| Average True Range (ATR) | 2.71 | 4.18 |
| MACD | -0.38 | 0.78 |
| Stochastic Oscillator | 11.49 | 63.24 |
Grupo Cibest SA is a full service financial group offering a broad range of financial products and services to a diversified individual and corporate clients through subsidiaries. Its network also includes offshore banking subsidiaries in Panama and Puerto Rico, as well as other adjacent businesses. Its products and services include Savings and Investment, Financing, Factoring, Financial and Operating Leases, Capital Markets, Trading, Cash Management, Foreign Currency and Trade Finance, Bancassurance and Insurance, Investment Banking, Trust and Fiduciary Services, Mortgage Lending Business, among others. Its segments include Banking Colombia, Banking El Salvador, Banking Guatemala, International Banking, Leases, All Other and Banking Panama.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.